UY27645A1 - Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn - Google Patents

Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn

Info

Publication number
UY27645A1
UY27645A1 UY27645A UY27645A UY27645A1 UY 27645 A1 UY27645 A1 UY 27645A1 UY 27645 A UY27645 A UY 27645A UY 27645 A UY27645 A UY 27645A UY 27645 A1 UY27645 A1 UY 27645A1
Authority
UY
Uruguay
Prior art keywords
dispersions
snlid
presinn
mctod
amorphes
Prior art date
Application number
UY27645A
Other languages
English (en)
Inventor
Ronald A Beyerinck
Ray Roderick
Dobry Daniel
Settell Dana
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27645A1 publication Critical patent/UY27645A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Glanulating (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

Dispersiones sólidas amorfas homogéneas de fármacos en polímeros mejoradores de la concentración se preparan en tamanos de partícula más grande adecuadas con minimo contenido de finos, utilizando un atomizador y condiciones de procedimiento capaces de producir gotas que tienen un diámetro medio de al menos 50 micrones y un D10 de al menos 10 micrones.
UY27645A 2002-02-01 2003-01-31 Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn UY27645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35398602P 2002-02-01 2002-02-01

Publications (1)

Publication Number Publication Date
UY27645A1 true UY27645A1 (es) 2003-09-30

Family

ID=27663274

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27645A UY27645A1 (es) 2002-02-01 2003-01-31 Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn

Country Status (20)

Country Link
US (1) US7780988B2 (es)
EP (1) EP1469830A2 (es)
JP (1) JP2005523260A (es)
KR (1) KR100758045B1 (es)
CN (1) CN1787808A (es)
AR (1) AR038369A1 (es)
AU (1) AU2003239463B2 (es)
BR (1) BR0307515A (es)
CA (1) CA2474958A1 (es)
GT (1) GT200300024A (es)
MX (1) MXPA04007435A (es)
PA (1) PA8565401A1 (es)
PE (1) PE20030804A1 (es)
PL (1) PL371593A1 (es)
RS (1) RS67304A (es)
RU (1) RU2288703C2 (es)
TW (1) TW200404576A (es)
UY (1) UY27645A1 (es)
WO (1) WO2003063821A2 (es)
ZA (1) ZA200405971B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CA2474958A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
ATE458476T1 (de) 2004-06-01 2010-03-15 Teva Gyogyszergyar Zartkoeruen Verfahren für die zubereitung der amorphen form eines medikamentes
CN101006076B (zh) 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
EP1817315A1 (en) 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Processes for producing crystalline macrolides
WO2006079921A2 (en) * 2005-01-28 2006-08-03 Pfizer Products Inc. Drying of drug-containing particles
EP1909762A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Amorphous efavirenz and the production thereof
CA2634056C (en) * 2005-12-21 2014-06-10 Eisai R&D Management Co., Ltd. Amorphous form of 1,2-dihydropyridine compound
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
EP1983966B1 (en) 2006-02-09 2013-06-26 Merck Sharp & Dohme Corp. Polymer formulations of cetp inhibitors
ES2372983T3 (es) * 2006-06-06 2012-01-30 Tibotec Pharmaceuticals Proceso para preparar formulaciones secadas por aspersión de tmc125.
PT2043610E (pt) 2006-07-21 2015-10-22 Bend Res Inc Secagem de partículas contendo fármacos
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
EP2093225A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
ES2873502T3 (es) 2009-03-27 2021-11-03 Bend Res Inc Proceso de secado por pulverización
CN103002878B (zh) 2010-04-09 2015-07-01 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
AU2011264993B2 (en) 2010-06-09 2014-02-06 Abbvie Bahamas Ltd. Solid dispersions containing kinase inhibitors
CN103037843A (zh) * 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
PT2611529T (pt) 2010-09-03 2019-05-09 Bend Res Inc Método de secagem por pulverização
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
DK2661254T3 (da) 2011-01-05 2017-11-06 Hospira Inc Sprøjtetørring af vancomycin
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
PT106063B (pt) * 2011-12-19 2017-05-30 Inst Superior Técnico Minociclina cristalina termorresistente produzida por recristalização com dióxido de carbono
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
CN104321059A (zh) 2012-05-31 2015-01-28 默沙东公司 食欲素受体拮抗剂的固体剂量制剂
RS62676B1 (sr) * 2012-09-11 2021-12-31 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
EP2950797B1 (en) 2013-02-01 2019-09-11 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
US9884067B2 (en) 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN103694903B (zh) * 2013-12-02 2015-07-01 南通瑞普埃尔生物工程有限公司 一种瞬干胶粘剂及其制备方法
KR20160093611A (ko) * 2013-12-05 2016-08-08 알라이즈 바이오시스템즈 게엠베하 경구 투여를 위한 약물 제제의 제조 방법
EP3171860A4 (en) 2014-07-25 2017-08-09 Laurent Pharmaceuticals Solid oral formulation of fenretinide
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP3212169B1 (en) 2014-10-31 2021-01-13 Bend Research, Inc. Process for forming active domains dispersed in a matrix
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
SI3226843T1 (sl) 2014-12-05 2021-11-30 Aragon Pharmaceuticals, Inc. Protirakavi sestavki
RU2585023C1 (ru) * 2014-12-18 2016-05-27 Общество с ограниченной ответственностью "Нанолек" Способ гранулирования
MX2018012557A (es) 2016-04-15 2019-07-04 Janssen Sciences Ireland Uc Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside.
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
WO2018075865A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions for the treatment of neurodegenerative diseases
CR20200378A (es) 2018-03-14 2021-01-08 Janssen Sciences Ireland Unlimited Co Régimen posológico del modulador del emsalblaje de la cápside
MX2021001063A (es) 2018-07-30 2021-04-12 Chugai Pharmaceutical Co Ltd Dispersion solida de derivado de hidantoina.
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
TW202136258A (zh) 2019-12-30 2021-10-01 美商迪賽孚爾製藥有限公司 １—（４—溴—５—（１—乙基—７—（甲胺基）—２—側氧基—１，２—二氫—１，６—萘啶—３—基）—２—氟苯基）—３—苯脲組合物
LT4084778T (lt) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1131242A (en) 1965-02-18 1968-10-23 Gen Foods Ltd Improvements in or relating to spray-drying apparatus
DE2201111A1 (de) 1971-01-19 1972-07-27 Niro Atomizer As Zerstaeubungstrocknungsvorrichtung zur Herstellung von Pulver,z.B. Milchpulver
IT1025765B (it) 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
DE2741196A1 (de) * 1977-09-13 1979-03-15 Bayer Ag Verfahren zur herstellung von perlpolymeren
US4187617A (en) 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4702799A (en) 1985-09-03 1987-10-27 Nestec S.A. Dryer and drying method
ES2163504T5 (es) 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
DE60042352D1 (de) 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2474958A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
KR100664822B1 (ko) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법

Also Published As

Publication number Publication date
KR100758045B1 (ko) 2007-09-11
GT200300024A (es) 2003-09-22
CA2474958A1 (en) 2003-08-07
WO2003063821A3 (en) 2003-11-13
KR20040083491A (ko) 2004-10-02
WO2003063821A2 (en) 2003-08-07
AR038369A1 (es) 2005-01-12
RU2004123639A (ru) 2005-04-20
US7780988B2 (en) 2010-08-24
RU2288703C2 (ru) 2006-12-10
US20030185893A1 (en) 2003-10-02
PE20030804A1 (es) 2003-09-19
PA8565401A1 (es) 2003-12-10
EP1469830A2 (en) 2004-10-27
PL371593A1 (en) 2005-06-27
AU2003239463B2 (en) 2007-10-18
RS67304A (en) 2006-10-27
CN1787808A (zh) 2006-06-14
TW200404576A (en) 2004-04-01
BR0307515A (pt) 2004-12-07
JP2005523260A (ja) 2005-08-04
MXPA04007435A (es) 2004-10-11
ZA200405971B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
UY27645A1 (es) Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn
TNSN03138A1 (en) PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AN AMORPHOUS MEDICINAL PRODUCT
WO2008129106A3 (es) Nanopartículas que comprenden una ciclodextrina y una molécula biológicamente activa y sus aplicaciones
AU2002243441A1 (en) Preparation of drug particles using evaporation precipitation into aqueous solutions
EP2283822A3 (en) Spray drying processes for forming solid amorphous dispersions of drugs and polymers
WO2009095562A3 (fr) Biomateriau permettant la delivrance controlee d'actifs
MY159380A (en) Controllable filler prefloculation using a dual polymer system
MX358592B (es) Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos.
SG170087A1 (en) Pharmaceutical compositions
WO2004032849A3 (en) Methods of administering fgf18
MXPA05007154A (es) Atomizador prepeliculizacion.
TW200740478A (en) Dispensing device
EA200600877A1 (ru) Наночастицы для доставки лекарств
MXPA04007438A (es) Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
WO2006065746A3 (en) Methods of treating ige-mediated disorders comprising the administration of high concentration anti-ige antibody formulations
DE60118395D1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen
MX2009005696A (es) Nanoparticulas magneticas para la aplicacion en hipertermia, preparacion de las mismas y uso en constructos que tienen una aplicacion farmacologica.
WO2007141344A3 (fr) Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
EP1847257A3 (en) Solid preparation comprising enteric solid dispersion
EP1688169A4 (en) METHOD FOR PRODUCING FINE PARTICLES OF AN ORGANIC COMPOUND
EP1847260A3 (en) Solid dispersion preparation
ATE438385T1 (de) Pharmazeutische zusammensetzung
WO2006097725A3 (en) Pharmaceutical compositions comprising microparticles for delivery into neurons
MX2009005947A (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas.
EP1886672A3 (en) Solid dosage form comprising solid dispersion and method for producing the same

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126